Underlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular thrombectomy

• DOI: 10.1016/j.jstrokecerebrovasdis.2023.107227
• Publication Date: 2023-07-10T23:07:50Z
• Authors: Tareq Kass-Hout; Rami Z. Morsi; Sonam Thind; Theodore Karrison; Harrison Lee; Fadi Nahab; Rishi Gupta; Julián Carrión-Pe...; Issam A. Awad; Elisheva Coleman; James R. Brorson; Cedric McKoy; Jacqueline Morales; Scott Mendelson; Ali Mansour; Shyam Prabhakaran
• Keywords: ICAD; Dyslipidemia; Stroke

Data on large vessel occlusion (LVO) management due to intracranial atherosclerotic disease (ICAD) are scarce.To compare clinical outcomes between patients with ICAD and those without ICAD following mechanical thrombectomy (MT).We performed a retrospective analysis of consecutive patients who underwent MT for LVO in a large academic comprehensive stroke center, and compared in-hospital mortality, 90-day mortality, favorable functional outcome at 90 days, and symptomatic intracranial hemorrhage (ICH) using chi-squared tests and multivariate logistic regression analyses. We defined ICAD as observable plaque at occlusion site post-thrombectomy.Among 215 patients (mean age 67.1 ± 16.0 years; 60.5% female; 83.6% Black, median NIHSS score 16), ICAD was present in 38 patients (17.7%). Diabetes and dyslipidemia were more common in those with ICAD (57.9% vs. 38.4%, p = 0.027 and 29.0% vs. 14.7%, p = 0.035, respectively). Substantial reperfusion (TICI ≥2b) was achieved less often (84.2% vs. 94.4%, p = 0.031) but symptomatic ICH was also less common in ICAD patients (0% vs. 9.0%, p = 0.081). In-hospital and 90-day mortality were more common (36.8% vs. 15.8%, p = 0.003 and 52.6% vs. 26.6%, p = 0.002, respectively) and favorable functional outcome (mRS 0-2) at 90 days was less common (7.9% vs. 33.9%, p = 0.001) in ICAD patients. After adjusting for prognostic variables, ICAD was independently associated with in-hospital mortality (OR=4.1, 95% CI 1.7-9.7), 90-day mortality (OR=3.7, 95% CI 1.6-8.6), and poor functional outcome at 90 days (OR=5.5, 95% CI 1.6-19.4).Symptomatic ICAD in a predominantly African American cohort is associated with increased odds of mortality and poor functional outcome at 90 days in patients with LVO undergoing MT.